Crude and adjusted colectomy rates in Swiss UC patients were lower than those reported previously in the literature, and decreased over time.
Introduction
UC refers to a chronic inflammatory condition of yet insufficiently understood aetiology, affecting the mucosal layer of the colon. Colectomy, hospitalisation due to severe flares, and colorectal cancer are amongst the most important adverse outcomes in patients with UC. [1] [2] [3] [4] [5] Main indications for colectomy in UC patients can typically be distinguished into emergent colectomy, with fulminant or refractory colitis, and subacute to chronic complications constituting indication for surgery in the setting of elective colectomy, with colonic dysplasia or cancer and intolerance to medical treatment as the main underlying indications necessitating surgery. 6, 7 In previous studies, rates of colectomy in UC patients were revealed to be highly variable over time and geographical location. In a retrospective population-based series from Sweden in 1990, high cumulative colectomy rates of 20% after 5 years, 28% after 10 years, and 45% after 25 years were described. 8 Similar results were reported in a Danish cohort from Copenhagen in 1994, with 24% of UC patients undergoing colectomy 10 years after diagnosis. 9 More recent studies, however, revealed considerably lower colectomy rates. The European Collaborative Study Group of Inflammatory Bowel Disease [EC-IBD] reported a cumulative 10-year colectomy rate of 8.7%. Intriguingly, a substantial difference in colectomy rates was discovered in northern [10. 4%] as compared with southern European centres [3.9%] . 10 Investigations by the Inflammatory Bowel South-Eastern Norway [IBSEN] Study Group determined a 1-year colectomy rate of 4%. 11 After 5 years, 7.5% of patients underwent colectomy; the majority among them [almost three out of four; 71%] within the first 2 years following diagnosis. 12 After 10 years of follow-up, the cumulative colectomy rate was 9.8% in this cohort. 13 Similarly, a Canadian populationbased study revealed 5-, 10-, and 20-year overall colectomy rates of 7.5%, 10.4%, and 14.8%, respectively. 14 In addition, researchers from the Mount Sinai Ulcerative Colitis Surveillance Database, including 561 patients, identified a colectomy rate of 17.3% over a median follow-up of 21.4 years. 2 These considerably lower colectomy rates compared with the Scandinavian population-based studies 8, 9 are most likely due to a multitude of reasons, including variations in diagnostic accuracy and referral bias, as well as substantial improvements in therapeutic opportunities over time. Regarding the latter, Kaplan et al. described steadily decreasing elective but stable emergent colectomy rates between 1997 to 2009, possibly due to an increase in use of immunomodulators and anti-tumour necrosis factor [TNF] . 7 In contrast, Jess et al. observed no significant change in surgery rates in Denmark from 1962 to 2005 in UC patients, reporting a fairly stable longterm prognosis over the past five decades. 15 Several risk factors have been associated with future need of colectomy. For instance, tobacco smoking has been described to exert a protective effect, with smokers being less likely to develop UC compared with non-smokers. [16] [17] [18] Further, several studies indicated active smoking to be associated with milder course of UC, including lower colectomy rates in some 19, 20 but not all 21 studies. Numerous studies identified male sex 13, 14, 22, 23 and disease extent at diagnosis as major risk factors. [7] [8] [9] [10] [11] [12] Patients with extensive colitis at diagnosis have a higher probability of colectomy compared with patients with proctitis and left-sided colitis, with an increasing risk over time in the case of disease progression from proctitis or left-sided colitis to extensive colitis during follow-up. 8, 10, 13 Extraintestinal manifestations [EIM] may worsen the course of disease and therefore be associated with higher risk for complications. For instance, the risk of developing dysplasia or colorectal cancer is substantially increased in UC patients with concomitant primary sclerosing cholangitis [PSC] , consecutively affecting colectomy rates. 3, 24 In a systematic review and meta-analysis including 71 studies, no difference in need for surgery was identified amongst those patients with versus without family history of UC. 25 Likewise, no difference in the course of disease, including need for surgery, was observed between familial and sporadic inflammatory bowel disease [IBD] cases in a population-based study in Norway. 26 In view of the currently limited and partially conflicting available literature on this topic, we aimed to investigate the cumulative rates of colectomy and potential changes thereof over time, as well as associated risk factors in UC patients in the Swiss Inflammatory Bowel Disease Cohort Study [SIBDCS].
Material and Methods

Patients
Starting in 2006, patients with an established diagnosis of IBD from all regions of Switzerland were included in the nationwide Swiss Inflammatory Bowel Disease Cohort Study [SIBDCS] 27 that is financially supported by the Swiss National Science Foundation [SNSF] and approved by the local ethics committees [EK-1316] . All patients provided written informed consent. Recruitment of patients is carried out in university hospitals, large non-university hospitals and private practices across Switzerland.
Patients with Crohn's disease [CD] , UC or colitis unclassified [CU] are included in the cohort if diagnosis was established at least 4 months before inclusion. At the time of inclusion, data acquisition focuses on clinical, socioeconomic, and psychosocial data. Patients then undergo a thorough clinical and laboratory assessment. Treating IBD physicians complete detailed questionnaires focusing on physician-reported outcomes, whereas patient-reported outcome questionnaires evaluate quality of life, social impairment, and symptoms. Follow-up occurs once a year and additionally in case of unscheduled events.
All patients within the SIBDCS with a diagnosis of UC established by a gastroenterologist [including patients having received their diagnosis of UC or having undergone colectomy before the initiation of the SIBDCS] were included in our analysis. We conducted an analysis of the prospectively collected data during SIBDCS follow-up, including disease history characteristics at enrolment in the cohort. Colectomy rates and time of diagnosis in SIBDCS patients before inclusion in the cohort could be assessed through enrolment and follow-up questionnaire data. 27 Non-smokers were defined as patients who had never smoked, either at diagnosis or during course of disease and follow-up in the SIBDCS; whereas ongoing smokers were defined as either patients who had been smoking at diagnosis of their UC and at least for one consecutive follow-up visit, or as patients not smoking at diagnosis but reporting smoking during follow-up at least once in the annual patient questionnaire. Smoking status is assessed at inclusion and also longitudinally in the annual patient as well as physician questionnaires of the SIBDCS. As smoking status enquired by the physician may be under-reported, we considered self-reporting in the patient questionnaire for our analysis. Continuous data distribution was assessed using Normal QQ-plots. Normally-distributed continuous variables were summarised as mean, standard deviation, and range. Non-Gaussian data were summarised as median, interquartile range [IQR] , and range. Differences in means between two groups for normally distributed data were assessed using Student's t-test, and differences in distribution for non-Normally distributed data were assessed using the Mann-Whitney Wilcoxon rank sum test. In case of more than two groups, analysis of variance [ANOVA], [respectively Kruskall-Wallis test], has been used.
Statistical analysis
Categorical data were summarised as raw frequencies and relative percentages. Differences in categorical data distribution between two or several groups have been assessed using the chi square test, or Fisher's exact test in case of insufficient sample size.
Cumulative rates of colectomy were analysed using survival analysis, including specific techniques to deal with left-and intervalcensored data. Kaplan-Meier curves were computed to analyse time to first occurrence of colectomy and to derive, for example, 10-year colectomy rates of complications, with 95% confidence intervals [CI] . The log-rank test was used to compare several survival curves, according to the different risk factors.
Multivariate logistic regression was used to assess association between colectomy rates and different risk factors. Crude yearly colectomy rates were computed with 95% confidence intervals. Adjusted yearly rates of colectomy were computed using multilevel mixed-effects logistic regression, by forcing a linear effect of calendar year on the logistic level. Adjustment has been made according to different risk factors.
Results
Baseline characteristics of patients and overall colectomy rates
We included a total of 1245 SIBDCS patients [680 male, 54.6%] with UC in our analysis, with a median disease duration of 11 years and median age at diagnosis of 31 years. Out of these 1245 patients, 114 underwent colectomy, with an overall 5-, 10-, 15 
Risk factors for colectomy
In a univariate analysis, we found male sex to be significantly associated with colectomy, with almost two-thirds of patients [64%] undergoing colectomy being male [female: OR = 0.65; p = 0.035]. Pancolitis at diagnosis was also a highly significant risk factor for colectomy, with a more than 20% higher proportion of patients with pancolitis among those UC patients undergoing colectomy as compared with their counterparts without colectomy during followup in the SIBDCS [left-sided colitis: OR 0.39; p < 0.002; proctitis: OR 0.25; p < 0.001]. Furthermore, we found younger age at diagnosis to be associated with higher colectomy rates [OR = 0.89 per 5 years of age; p = 0.006]. In addition, there was a non-significant association of positive family history of IBD with higher colectomy rates [OR = 1.69; p = 0.060; Tables 1 and 2] .
In multivariate analyses, pancolitis at diagnosis [OR = 2.16; p = 0.005] and disease duration [OR = 1.04; p = 0.001] were revealed to be independently associated with colectomy, whereas sex or age at diagnosis were not [ Table 2 ]. A statistically significant linear diminishing trend with year on the logistic level for colectomy rates was found (beta coefficient = -0.210 [-0.323--0.097]; p < 0.001) when adjusting for gender, age at diagnosis, disease duration, and previous use of anti-TNF agent.
EIM and colectomy
We found a significantly higher fraction of patients suffering from concomitant extraintestinal manifestations [EIM] at any time in their entire history of disease, with 59.6% in patients with as compared with 39.1% in those without colectomy [OR = 2.30; p < 0.001]. This increase in risk was observed for EIM overall and several individual EIM [ Table 1 ].
Smoking and colectomy
At the last assessment before colectomy, 89.3% of the patients were non-smokers [ Table 3 ]. Smoking did not have a significant protective effect on the risk of colectomy overall in the SIBDC; however, a potential protection might have occurred in smoking male patients [OR = 0.64; p = 0.106]. Likewise, considering only the most recent smoking status [i.e. at latest follow-up or at follow-up preceding surgery] we did not observe any significant protective effects in the whole study population, nor in the subgroups of male or female patients. 
Disease duration and colectomy
Overall colectomy rates were highest in the 10-20 years following UC diagnosis [ Table 4 ], and numerically the majority of colectomies were performed within 10 years after UC diagnosis. The highest fraction of patients undergoing colectomy had their diagnosis before 1997 [ Table 5 ].
In view of the fact that crude numbers of colectomy have to be interpreted with caution [increase in overall risk in patients with longer follow-up], we subsequently analysed our data in addition in a time-to-event fashion with the survival approach, revealing a colectomy-free survival of 0.936, 0.856, and 0.816 after 10, 20, and 30 years of disease duration, respectively [ Figure 1 ]. As shown by the smoothed hazard function [depicting the instantaneous colectomy risk at an exact time, conditional on survival until then], we found the risk of colectomy to initially increase after 10 years, reaching a peak after about 15 years of disease duration, and to subsequently decrease to considerably lower risk rates [ Figure 2 , Table 4 ].
Time trends in colectomy rates: [evolution of colectomy rates over time]
We observed a decrease in colectomy rates over time, with evident nominal decrease in absolute numbers of annual colectomies performed [as well as the incident rate of colectomy] after 2010 
Discussion
In this study we investigated the risk of colectomy in a large prospective cohort of UC patients over a considerable, prospective, long-term follow-up with a median disease duration of 11 years [with a range up to 50 years, IQR 6 to 18 years]. We would like to emphasise the following key findings. First, we found overall colectomy rates in our cohort at the lower end of or even lower than those described in previous literature. Second, we identified significantly decreasing colectomy rates in Swiss UC patients within recent years. Third, the risk of colectomy according to disease duration follows a bell-shaped curve, with a monotonous increase in colectomy rates during the first 15 years after diagnosis, followed by a subsequent decrease in colectomy risk.
The overall reduction of colectomy rates represents an encouraging signal for patients with recently diagnosed UC as well as those with a disease duration of over 20 years.
Our results reveal considerably lower cumulative colectomy rates of 4.1%, 6.3%, 10.5%. and 14.8% after 5-, 10-, 15-. and 20 years, respectively, as compared with historical studies [20.0-23.7%, 28.0-29.9%, and 32.4-45.0% after 10, 15, and 20 years, respectively]. 8, 9 In addition to that, our observed cumulative rates also appear in line with 2, 13, 14 or slightly lower than those observed in more recent investigations [7.6% and 9.8% after 5 and 10 years, 13 and 7.5% 12 and 10.4% 14 after 5 and 10 years, respectively]. In terms of risk factors for colectomy, our study confirmed male sex 13, 14, 22, 23 [almost twice as many colectomies were performed on male patients], lower median age at diagnosis [in accordance with 13, 29 Our study showed individual EIM to be significantly associated with colectomy; in particular arthralgia was present in almost half of all colectomised patients. This is in line with population-based studies from France in children, 30 adults, 31 or both. 32 Interestingly, in the the latter, EIM were a rather strong risk factor for a composite endpoint of complications [including use of immunosuppressants or biologics, or need of colectomy].
It has been repetitively described that tobacco smoking is protective against UC and associated with a milder course of disease, [16] [17] [18] but a potential protective effect on the risk of colectomy remains dubious and unproven. 10, 33, 34 Likewise, our results do not support a negative effect of smoking cessation or non-smoking on the overall risk of colectomy. Our results thus provide further rationale to encourage smoking cessation even in severe UC cases and to ultimately discard still widely prevalent concerns among both physicians and patients about this step.
Regarding evolution of colectomy rates over time, our findings indicate a clear decrease. However, if necessary, colectomy is increasingly performed early in the course of disease as reported in previous studies. [12] [13] [14] 35 Our finding of a significantly earlier performance of colectomy in recently diagnosed patients may point to an increased awareness and prompter diagnosis, as well as an increasingly early administration of potent and/or novel medical treatment after diagnosis, i.e. following a rapid step-up approach. The latter potentially translates into a benefit for our patients, with shorter period of time lost with futile medical therapies. A tendency towards a more aggressive treatment approach early in the course of disease may suit as an explanation for both the decrease in overall rates of colectomy in UC patients on the one hand, and an increasingly short interval between diagnosis and colectomy on the other. In view of a more rapidly enabled treatment escalation, it may be speculated that the peak of colectomy risk after diagnosis [ Figure 2 ] may occur even earlier after diagnosis in the future, whereas the overall risk of colectomy may continuously decrease. Regarding the latter, an earlier and more frequent use of immunomodulators and the introduction of biologics has been shown to reduce the requirement for surgery in the long term. 1 Our study has several limitations. Prospective data acquisition in the cohort started only in 2006, so antecedent data are retrospective. Thus, we cannot exclude a recruitment bias affecting colectomy rates before 2006. For instance, if patients underwent colectomy before prospective data acquisition, these patients might not have been included in the cohort at all, potentially leading to a relevant underestimation of the colectomy rate before 2006. Yet, in clinical practice in Switzerland, UC patients with a very severe disease course previously requiring colectomy, in most instances will remain under the care of a gastroenterologist with special expertise in IBD, therefore increasing the likelihood of SIBDCS inclusion. Moreover, the SIBDCS is not fully population-based, with a tendency towards a higher fraction of patients being treated in tertiary referral centres. On the other hand, 80% of admitted IBD patients were included by gastroenterologists working in hospitals and 20% from gastroenterologists in private practices. Whereas in the latter, mild-moderate cases presumably with intrinsically lower risk of colectomy predominate, we cannot exclude that differences in the timely initiation and escalation of medical treatment may influence colectomy rates across treating physicians. The overall colectomy rates derived in our cohort may even have been overestimated as a net effect of the aforementioned factors, and thus may be even lower in the entire Swiss IBD population.
Our study also has several strengths. Our results found on a relatively long observational time and disease duration,with a range of 0-50 years. Moreover, the SIBDCS follows a rigid and wellstructured prospective data acquisition, with yearly follow-up by physician-as well as patient-based data acquisition, in contrast to several other studies on this topic which are largely or exclusively based on retrospective data acquisition.
In conclusion, we identified overall colectomy rates to be lower than expected based on clinical experience as well as studies from recent decades, including virtually all those described in the more recent literature. Our data suggest a biphasic disease course, with an initial increase of colectomy rates within 10 years after diagnosis and subsequent decline in colectomy risk after 15 years. Colectomy risk was lowest 20-30 years after diagnosis. We found male sex, family history, pancolitis, younger age, and presence of EIM to be significant risk factors for colectomy, whereas no clear protective effect of smoking was identified. Furthermore, colectomy rates significantly decreased in Swiss UC patients, and the overall lowest colectomy rates were observed in the last 3 years of observation between 2013-2015. These findings are reassuring for UC patients and indicate an increase in the overall efficacy of medical treatment in recent years. 
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